

Ototoxicity and otoprotective agents market report

Reasons to invest

The number of people in the USA and western Europe undergoing cisplatin chemotherapy each year who could have their hearing protected is:

1 million

The value of the cancer support therapy market is:

\$8 billion

The potential value of an otoprotectant targeting cisplatin-induced hearing loss is:

\$250 million

Ototoxicity and otoprotective agents market report answers the following key questions:

- What is the size of the otoprotection market in the USA and western Europe?
- What are the treatment pathways?
- Who are the leading players and competitors?
- What are the current ototoxic drugs and their effects?
- Which research avenues should be explored to identify potential leads?



What's the next step?

- We can send you a **FREE** executive summary of this report.
- We can discuss with you – face to face – how your technologies could address the needs of these markets.
- We can foster collaboration through our extensive network of academic researchers and companies already working in this sector.

Other executive summaries and market reports in this series:

- Cochlear implants
- Presbycusis (age-related hearing loss)
- Tinnitus

If you are interested in receiving these, please contact us.

To find out more

Call us on **+44 (0)20 7294 3742** (textphone **18001 020 7294 3742**) email us at **research@rnid.org.uk** or go online **www.rnid.org.uk/marketreports**

RNID • 

Changing the world for deaf and hard of hearing people